{"id":"W4281653962","doi":"10.1200/jco.2022.40.16_suppl.7551","title":"Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Oxaliplatin; Internal medicine; Tolerability; Gemcitabine; Neutropenia; Diffuse large B-cell lymphoma; Rituximab; Clinical endpoint; Adverse effect; Gastroenterology; Phases of clinical research; Oncology; Surgery; Lymphoma; Clinical trial; Chemotherapy; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006225844,0.0002366891,0.002164269,0.0003551756,0.0001538415,0.000008303412,0.0003771954,0.0002563012,0.00004201999],"category_scores_gemma":[0.007167997,0.0001502193,0.0003180056,0.0005238964,0.0004314575,0.000156857,0.0005288769,0.002202783,0.000001425231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001392624,"about_ca_system_score_gemma":0.004015293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003420121,"about_ca_topic_score_gemma":0.0006924275,"domain_scores_codex":[0.9921636,0.002036897,0.003732977,0.0003659086,0.001196801,0.0005038352],"domain_scores_gemma":[0.9926516,0.003697855,0.002589944,0.0003973041,0.0003604264,0.0003029075],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8389443,0.0746349,0.06509681,0.00008546111,0.0002915042,0.0007355252,0.001583369,0.00001409338,0.00004399027,0.0000425046,0.002511361,0.01601617],"study_design_scores_gemma":[0.7313346,0.03914619,0.2017021,0.0001463761,0.000155072,0.00003924815,0.0005996951,0.0001082142,0.00001616154,0.00004002356,0.02659256,0.000119803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926678,0.000703543,0.000005127069,0.002936155,0.001023824,0.001072358,0.0001300812,0.000006823755,0.001454306],"genre_scores_gemma":[0.997909,0.0004283884,0.0001820001,0.000804493,0.0004081612,0.00002055318,0.00001354122,0.00003189409,0.000201965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1366053,"threshold_uncertainty_score":0.9570118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05272054963104936,"score_gpt":0.428999063772115,"score_spread":0.3762785141410656,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}